Early detection, early diagnosis and early treatment have greatly increased the 5-year cure rate of malignant tumors, which has become a controllable “chronic disease”. Oncologists emphasize that many malignant tumors can be prevented and controlled by maintaining a healthy lifestyle and diet, insisting on medical checkups, and dealing with precancerous lesions in time. Tumor markers are one of the effective means to detect the presence of malignant tumors in human body. Different combinations of tumor markers suggest different parts of tumors, which can be checked once a year. Of course, it does not mean that if the tumor markers are increased, then 100% of the people are suffering from malignant tumor, further diagnosis is needed. Nowadays, people pay more attention to malignant tumors, and there are some phenomena of over-checking and over-panic, which is undesirable. If the tumor marker happens to be inflammatory in the body when the tester is tested, the tumor marker may also be elevated. As long as it is not rapidly and continuously elevated, it is not necessarily a malignant tumor. Of course, it is prudent to have a shorter follow-up interval after the increase of tumor markers. For example, a normal person above 45 years old should have a colonoscopy once every 5 years to prevent colorectal cancer, but after the increase of tumor markers, it can be advanced to 1 colonoscopy in 2 years, and if you are still not sure, you can have a check once a year, but it is not necessary to check every month at all. Secondly, malignant tumor needs multidisciplinary comprehensive treatment Malignant tumor is a kind of systemic disease, and it is difficult to achieve tumor cure by one kind of treatment alone. At the end of last century, many medical scientists and famous scholars and professors put forward the principle of multidisciplinary comprehensive treatment. It is to apply the existing treatments in a planned and rational way according to the patient’s body condition, pathological type, invasion range (disease stage) and development trend of tumor, in order to improve the cure rate, prolong the survival period and improve the quality of life of patients. Multidisciplinary comprehensive treatment has achieved good results in clinical practice and scientific research. Multidisciplinary comprehensive treatment of tumor is not a simple combination of surgery, chemotherapy, radiotherapy, biological treatment and Chinese medicine treatment, but a planned, step-by-step and sequential individualized treatment collection. The individualized tumor treatment plan should be reasonably designed according to the patient’s general condition, pathological type and taking into account the systemic condition and local condition, survival rate and quality of life, tumor load and immune status of the body, cost and benefit, Chinese medicine and Western medicine and other factors. Molecular targeted therapy may become mainstream in the future. Since traditional tumor drug therapy generally refers to chemotherapy, which has the characteristics of “no distinction between the enemy and me, you die and I live” and large toxicity, nowadays targeted therapy has become a more widely used treatment in the field of tumor therapy. At present, molecular targeted therapy has overturned the traditional treatment mode in the treatment of kidney cancer, non-small cell lung cancer, malignant melanoma and mesenchymal tumor. Take non-small cell lung cancer treatment as an example, in the past, the efficiency of traditional chemotherapy, i.e. the proportion of effective reduction of lesion extent, always hovered around 20% to 30%, and the survival rate was 9 to 10 months. With molecular targeted therapy, if EFGR and ALK gene mutations are detected through genetic examination before chemotherapy, the physician can administer relevant targeted drugs that can inhibit such gene mutations, and the treatment efficiency can be doubled to more than 50% to 60%, and the survival rate can be extended to 18 months. Also, this approach has been significantly more effective in the treatment of bowel cancer, breast cancer, lymphoma and other tumors. Nowadays, many molecular targeted drugs are oral formulations, which are also more convenient and safe in terms of medication, creating conditions for many patients to be treated at home, and providing the possibility for malignant tumors to be transformed into chronic disease treatment. Therapeutic vaccines may cure malignant tumors The research results of 2011 Nobel Prize winner Ralph Steinman and others are the key principles of immune system activation, and one of its clinical applications is therapeutic vaccines. Therapeutic vaccines are used to cure diseases by inducing a specific immune response to remove pathogens or diseased cells in an organism that has been infected with pathogenic microorganisms or has suffered from certain diseases. The dendritic cell vaccine (DC vaccine for short) is a therapeutic vaccine, and in September 2010, the U.S. Food and Drug Administration (FDA) approved the first DC vaccine for the treatment of metastatic prostate cancer. “To be approved by the harsh FDA for clinical application in advanced tumors shows that the DC vaccine is indeed promising.” The tumor DC vaccine research conducted in the Department of Oncology at Southern Hospital has also received funding from the National Natural Science Foundation of China and the Guangdong Provincial Natural Science Foundation. The results of the previous study confirmed that the immune cells induced by the tumor DC vaccine can specifically kill tumor cells. “And in clinical treatment, we also found that for patients with advanced tumors, targeted therapy has a synergistic effect with cellular immunotherapy, and patients with good immune status have a longer remission period with targeted therapy. Therefore, on the basis of targeted therapy, combined with therapeutic vaccine will be a good treatment mode, and once successful, patients will be able to rely on their own immunity to cure the disease completely. Tumor biotherapy is the key to future tumor treatment. With the in-depth research on tumor biological behavior, tumor biotherapy is expected to become the dominant treatment for most tumors in the next 10-20 years.